Contact Us   |   Print Page   |   Sign In   |   Join
BioArbor March 2018
Tell a Friend About This EventTell a Friend

BioArbor events are open to the public and are especially suited for those interested in starting or growing life science businesses.

When: Wednesday, March 14, 2018
Where: Ann Arbor SPARK Central Innovation Center
330 E. Liberty Street
Lower Level
Ann Arbor, Michigan  48104
United States
Contact: Kate Oesterle

Online registration is closed.
« Go to Upcoming Event List  

Fostering Bioscience Innovation Through Diversity in Leadership

We know women file proportionately fewer invention disclosures and patents, launch fewer startup companies, are less successful at attracting investment funding, and are insufficiently represented in executive ranks and boardrooms. Simultaneously, we are seeing that companies with more women in senior leadership positions appear to have better economic practices and developments. So what are the drivers behind these dynamics, what challenges are women facing, how do we insure a diverse STEM workforce for the future, and what does everyone in the bio-industry need to do to make a difference and deliver the benefits of gender diversity for corporate performance?



Stephanie Morley, DVM
Co-Founder, COO and VP of Product Development, Zomedica


As the Chief Operations Officer and Vice President of Product Development, Stephanie L. Morley, DVM, leads Zomedica’s veterinary and innovation strategies, product development activities, research and development, and facilitates new business opportunities to ensure the delivery of affordable, high quality veterinary products by aligning customer needs, translational technologies, and corporate objectives.

Dr. Morley is a trained veterinarian with instinctive business acumen. Over the course of her 15 year career, she has become known as a transformational leader, experienced in building viable business units and overseeing departments with 600 plus staff and annual budgets totaling US$40 million in operating expenses. After earning a Bachelor of Arts in hospitality business and doctor of veterinary medicine from Michigan State University, Dr. Morley was a practicing veterinarian with Oakwood Animal Hospital in Kalamazoo, MI and Adobe Animal Medical Center in Albuquerque, NM where she quickly learned to juggle the roles of both clinical practitioner and operations management. During her tenure with MPI Research, she was rapidly promoted to increasingly responsible positions, advancing from lower-level supervisory roles to Vice President of Operations by building rapport with divisions and departments to instill a cohesive team atmosphere. As Associate Director of Business Development with the University of Michigan Medical School, Dr. Morley bridged communications between faculty members and external industry, translating science to business and business to science, in efforts to fast track innovations from discovery insight to market impact.

When she is not building the business, Dr. Morley can be found downhill skiing or tackling home improvement projects alongside her husband and their five children. Her personal tenet is to have fun in all endeavors and be the best example possible to her family, friends, community and professional network that are part of her journey.






Christine Gibbons
Co-Founder and COO, Histosonics


Chris has over thirty years of financial management, fundraising and operating experience and for the past twenty years has been deeply involved with early-stage emerging technology companies, both as an investor and part of entrepreneurial management teams.  Together with other founders, she raised over $85 million in start-up capital to launch and support fourteen new ventures.

Chris is currently Co-Founder and Chief Operating Officer of HistoSonics, Inc., a medical device company developing a non-invasive, image-guided, highly precise tissue ablation technology for cost effective treatments of significant cancers and diseases. She served the company in various roles including president, chief operating officer and interim chief executive officer.  Prior to HistoSonics, she held various leadership roles in entrepreneurial ventures including Executive in Residence (EIR) for Venture Investors, LLC, chief financial officer for Sensicore, a company with lab-on-a-chip sensor products (acquired by a division of GE), VP of Finance for Ardesta, an investor in “small-tech” opportunities and Partner and CFO of Seaflower Ventures, a venture capital firm focused on early-stage biomedical opportunities.

Chris is a board member of ONL Therapeutics, an Advisor to Apjohn Ventures Fund LP, a member of UM’s Venture Center Council and an advisory board member of Michigan State University’s Center for Venture Capital, Private Equity and Entrepreneurial Finance.  She served  on the Technical Oversight Committee for the Coulter Program at the University of Michigan from 2008 – 2016 and serves as a guest lecturer at Michigan State University’s Business School.  Chris holds an MBA from Wayne State University and a BA from Michigan State University.



Christine Haakenson, PhD

Former President and COO, Rubicon Genomics
Former CEO, Parabricks


Christine Haakenson served from 2012 to 2017 as President and Chief Operating Officer of Rubicon Genomics, which developed and manufactured innovative nucleic acid library preparation products for Next Generation Sequencing.  She was responsible for the company’s manufacturing, quality control, product development, internal operations, and business development.  During this period, Rubicon Genomics grew at a 48% CAGR and was acquired by TakaraBio in 2017.  From 2007-2011, she was the Chief Scientific Officer at the Canine Health Foundation where she was responsible for the Foundation’s funding program of world-wide research.  Previously, she spent 6 years at Accenture where she managed consulting projects in the pharmaceutical industry.

Christine is current business advisor and former CEO for Parabricks, an University of Michigan start-up company accelerating the genomic analysis through high performance GPU computing.

She holds a BS degree in chemical engineering from Cornell University and a PhD degree in biochemistry and molecular biology from Georgetown University.



Adrienne Harris, MEng

Product Development Manager, In2Being

Co-Founder/Former VP Operations and Director of Product Development, Tangent Medical


Adrienne Harris is a medical device development leader who works with inventors, entrepreneurs, investors, and manufacturers to take medical device ideas from concept to market.

Adrienne co-invented the NovaCath Integrated IV Catheter System while at the University of Michigan Medical Innovation Center in 2008 and co-founded Tangent Medical Technologies, Inc. in 2009 to develop the NovaCath into a commercial product. Over the course of 7 years, the Tangent team achieved two FDA 510(k) clearances, received multiple US and OUS patents, earned ISO 13845 and CE mark for European sales, as well as numerous other country-specific clearances. In bringing the NovaCath to market, Adrienne worked heavily with both onshore and offshore manufacturing vendors and supported several FDA and ISO audits. Tangent was acquired in April of 2016 by ICU Medical and the NovaCath was relaunched under the ICU nameplate in 2017.

Now in her role as a product development manager at in2being, Adrienne has brought her practical approach to product development to multiple unique client projects driving towards a range of market and regulatory goals.

Adrienne holds a Masters in Biomedical Engineering from the University of Michigan.


MichBio is a proud sponsor of BioArbor!

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal